2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Tae9,Globally, 968 350 new cases and 659 853 deaths from gastric cancer were reported in 2022. In the US, 30 300 new cases and 10 780 deaths were estimated in 2025. Gastric cancer is more common in men, and the median age at diagnosis is 68 years. Most gastric cancers (>90%) are adenocarcinomas. Worldwide, 85% of cases arise from the stomach body or antrum and 15% from the cardia. In the US, more than 90% of patients diagnosed with gastric cancer present with symptoms such as weight loss and abdominal pain. At presentation, approximately 13% have localized disease (limited to the stomach), 15% to 25% have locally advanced disease, defined as a tumor that has spread to regional lymph nodes, and 35% to 65% have metastatic disease. Helicobacter pylori infection is a treatable risk factor associated with 90% of gastric body and antrum cancers globally. Additional modifiable risk factors include smoking, alcohol, obesity, and salt intake. In countries with high incidence such as Japan and Korea, routine endoscopic screening beginning at age 40 years is associated with improved survival. Diagnosis is made by endoscopic biopsy. Patients with localized gastric cancer are treated with surgical resection and have a 5-year relative survival rate of 75% with treatment. Patients with more advanced-stage disease should receive gastrectomy, perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel and immunotherapy (durvalumab). Metastatic or unresectable disease may be treated with chemotherapy, immunotherapy, and/or targeted therapy depending on biomarkers, including programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (ERBB2; formerly HER2 or HER2/neu), and claudin-18, isoform 2 (CLDN18.2). For PD-L1-expressing gastric cancer, adding immune checkpoint inhibitors, such as nivolumab and pembrolizumab, is associated with an additional 3 months of survival when compared with chemotherapy alone. For gastric cancers overexpressing the ERBB2 or CLDN18.2 proteins, the addition of trastuzumab or zolbetuximab, respectively, is associated with an additional 3 to 4 months' survival. Early supportive care focusing on symptom management and on nutritional and psychosocial support is associated with 3 months of survival benefit. Less than 10% of patients with metastatic gastric cancer survive more than 5 years. Approximately 30 300 new cases of gastric cancer are diagnosed annually in the US. Localized gastric cancer is treated with gastrectomy, and locally advanced disease is treated with surgery and chemoimmunotherapy. For patients with unresectable or metastatic gastric cancer, chemotherapy with immune checkpoint inhibitors and targeted therapies such as trastuzumab or zolbetuximab improves survival by several months.31:Te7b, Importance Globally, 968 350 new cases and 659 853 deaths from gastric cancer were reported in 2022. In the US, 30 300 new cases and 10 780 deaths were estimated in 2025. Observations Gastric cancer is more common in men, and the median age at diagnosis is 68 years. Most gastric cancers (&gt;90%) are adenocarcinomas. Worldwide, 85% of cases arise from the stomach body or antrum and 15% from the cardia. In the US, more than 90% of patients diagnosed with gastric cancer present with symptoms such as weight loss and abdominal pain. At presentation, approximately 13% have localized disease (limited to the stomach), 15% to 25% have locally advanced disease, defined as a tumor that has spread to regional lymph nodes, and 35% to 65% have metastatic disease. Helicobacter pylori infection is a treatable risk factor associated with 90% of gastric body and antrum cancers globally. Additional modifiable risk factors include smoking, alcohol, obesity, and salt intake. In countries with high incidence such as Japan and Korea, routine endoscopic screening beginning at age 40 years is associated with improved survival. Diagnosis is made by endoscopic biopsy. Patients with localized gastric cancer are treated with surgical resection and have a 5-year relative survival rate of 75% with treatment. Patients with more advanced-stage disease should receive gastrectomy, perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel and immunotherapy (durvalumab). Metastatic or unresectable disease may be treated with chemotherapy, immunotherapy, and/or targeted therapy depending on biomarkers, including programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 ( ERBB2 ; formerly HER2 or HER2/neu ), and claudin-18, isoform 2 (CLDN18.2). For PD-L1–expressing gastric cancer, adding immune checkpoint inhibitors, such as nivolumab and pembrolizumab, is associated with an additional 3 months of survival when compared with chemotherapy alone. For gastric cancers overexpressing the ERBB2 or CLDN18.2 proteins, the addition of trastuzumab or zolbetuximab, respectively, is associated with an additional 3 to 4 months’ survival. Early supportive care focusing on symptom management and on nutritional and psychosocial support is associated with 3 months of survival benefit. Less than 10% of patients with metastatic gastric cancer survive more than 5 years. Conclusions and Relevance Approximately 30 300 new cases of gastric cancer are diagnosed annually in the US. Localized gastric cancer is treated with gastrectomy, and locally advanced disease is treated with surgery and chemoimmunotherapy. For patients with unresectable or metastatic gastric cancer, chemotherapy with immune checkpoint inhibitors and targeted therapies such as trastuzumab or zolbetuximab improves survival by several months. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"CLDN18.2 Antibody: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on CLDN18.2 Antibody (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/CLDN18.2%20Antibody\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"CLDN18.2 Antibody\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/CLDN18.2%20Antibody\"}]}}"}}]],["$","$L2f",null,{"title":"CLDN18.2 Antibody: Research & Clinical Takeaways","description":"Review evidence by treatment modality: CLDN18.2 Antibody — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jama.2025.20034","pmid":"41499132","title":"Gastric Cancer","journal_title":"JAMA","journal_issn":"0098-7484","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.1001/jama.2025.20034","source_score":190,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.1001/jama.2025.20034","days":"7","issn":"0098-7484","rank":"9","field":"Clinical Medicine","score":"190","category":"Medicine, General & Internal","categories":["Medicine, General & Internal"],"_categories":["Medicine, General & Internal"]},"pubmed":{"doi":"10.1001/jama.2025.20034","title":"Gastric Cancer: A Review.","journal":"JAMA","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41499132","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1001/jama.2025.20034","URL":"https://doi.org/10.1001/jama.2025.20034","ISSN":["0098-7484"],"link":[{"URL":"https://jamanetwork.com/journals/jama/articlepdf/2843616/jama_patel_2026_rv_250035_1767115812.09443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Gastric Cancer"],"author":[{"given":"Anuj Kishor","family":"Patel","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Nilay S.","family":"Sethi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Haeseong","family":"Park","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2026,1,7]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:31:01Z","timestamp":1767803461000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-08T04:04:15Z","timestamp":1767845055062,"date-parts":[[2026,1,8]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jama/fullarticle/2843616"}},"subtitle":["A Review"],"deposited":{"date-time":"2026-01-07T16:31:02Z","timestamp":1767803462000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"0098-7484"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.3322/caac.21834","key":"jrv250035r1","year":"2024","issue":"3","author":"Bray","volume":"74","first-page":"229","unstructured":null,"article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","journal-title":"CA Cancer J Clin","doi-asserted-by":"publisher"},{"DOI":"10.3322/caac.21871","key":"jrv250035r2","year":"2025","issue":"1","author":"Siegel","volume":"75","first-page":"10","unstructured":null,"article-title":"Cancer statistics, 2025.","journal-title":"CA Cancer J Clin","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-13-1057","key":"jrv250035r3","year":"2014","issue":"5","author":"Karimi","volume":"23","first-page":"700","unstructured":null,"article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2011.04.038","key":"jrv250035r4","year":"2011","issue":"3","author":"Ahn","volume":"74","first-page":"485","unstructured":null,"article-title":"Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2025.10218","key":"jrv250035r5","year":"2025","issue":"15","author":"Jayakrishnan","volume":"334","first-page":"1373","unstructured":null,"article-title":"Early-onset gastrointestinal cancers: a review.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2020-321600","key":"jrv250035r6","year":"2020","issue":"9","author":"Arnold","volume":"69","first-page":"1564","unstructured":null,"article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018.","journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(19)30488-7","key":"jrv250035r7","year":"2020","issue":"2","author":"de Martel","volume":"8","first-page":"e180","unstructured":null,"article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa001999","key":"jrv250035r8","year":"2001","issue":"11","author":"Uemura","volume":"345","first-page":"784","unstructured":null,"article-title":"Helicobacter pylori infection and the development of gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2023.12.022","key":"jrv250035r9","year":"2024","issue":"4","author":"Chen","volume":"166","first-page":"605","unstructured":null,"article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cgh.2022.07.042","key":"jrv250035r10","year":"2023","issue":"4","author":"Hirabayashi","volume":"21","first-page":"922","unstructured":null,"article-title":"Estimating the global burden of Epstein-Barr virus–associated gastric cancer: a systematic review and meta-analysis.","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers13153844","key":"jrv250035r11","year":"2021","issue":"15","author":"Vitelli-Storelli","volume":"13","first-page":"3844","unstructured":null,"article-title":"Family history and gastric cancer risk: a pooled investigation in the Stomach Cancer Pooling (STOP) project consortium.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1097/CEJ.0000000000000290","key":"jrv250035r12","year":"2018","issue":"2","author":"Praud","volume":"27","first-page":"124","unstructured":null,"article-title":"Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (STOP) project.","journal-title":"Eur J Cancer Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.canep.2018.04.009","key":"jrv250035r13","year":"2018","issue":null,"author":"Ferro","volume":"54","first-page":"125","unstructured":null,"article-title":"Alcohol intake and gastric cancer: meta-analyses of published data versus individual participant data pooled analyses (STOP project).","journal-title":"Cancer Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1097/CEJ.0000000000000874","key":"jrv250035r14","year":"2024","issue":"5","author":"Pelucchi","volume":"33","first-page":"433","unstructured":null,"article-title":"The global gastric cancer consortium: an update from the Stomach Cancer Pooling (STOP) project.","journal-title":"Eur J Cancer Prev","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-022-01565-y","key":"jrv250035r15","year":"2022","issue":"5","author":"Morais","volume":"33","first-page":"779","unstructured":null,"article-title":"Salt intake and gastric cancer: a pooled analysis within the Stomach Cancer Pooling (STOP) project.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers14194905","key":"jrv250035r16","year":"2022","issue":"19","author":"Paragomi","volume":"14","first-page":"4905","unstructured":null,"article-title":"The association between peptic ulcer disease and gastric cancer: results from the Stomach Cancer Pooling (STOP) project consortium.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-004-3485-7","key":"jrv250035r17","year":"2005","issue":"3","author":"Lindblad","volume":"16","first-page":"285","unstructured":null,"article-title":"Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-13-0042","key":"jrv250035r18","year":"2013","issue":"8","author":"Chen","volume":"22","first-page":"1395","unstructured":null,"article-title":"Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(14)71016-2","key":"jrv250035r19","year":"2015","issue":"2","author":"Oliveira","volume":"16","first-page":"e60","unstructured":null,"article-title":"Familial gastric cancer: genetic susceptibility, pathology, and implications for management.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2014.168","key":"jrv250035r20","year":"2015","issue":"1","author":"Hansford","volume":"1","first-page":"23","unstructured":null,"article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2211807","key":"jrv250035r21","year":"2023","issue":"13","author":"Usui","volume":"388","first-page":"1181","unstructured":null,"article-title":"Helicobacter pylori, homologous-recombination genes, and gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2022.10.026","key":"jrv250035r22","year":"2023","issue":"3","author":"Singh","volume":"97","first-page":"407","unstructured":null,"article-title":"Occurrence of gastric cancer in patients with juvenile polyposis syndrome: a systematic review and meta-analysis.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1038/ajg.2009.725","key":"jrv250035r23","year":"2010","issue":"6","author":"van Lier","volume":"105","first-page":"1258","unstructured":null,"article-title":"High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.","journal-title":"Am J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers14235953","key":"jrv250035r24","year":"2022","issue":"23","author":"Buckley","volume":"14","first-page":"5953","unstructured":null,"article-title":"Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.21.02112","key":"jrv250035r25","year":"2022","issue":"14","author":"Li","volume":"40","first-page":"1529","unstructured":null,"article-title":"Cancer risks associated With BRCA1 and BRCA2 pathogenic variants.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2022.0476","key":"jrv250035r26","year":"2022","issue":"6","author":"Momozawa","volume":"8","first-page":"871","unstructured":null,"article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1708423","key":"jrv250035r27","year":"2018","issue":"12","author":"Choi","volume":"378","first-page":"1085","unstructured":null,"article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1909666","key":"jrv250035r28","year":"2020","issue":"5","author":"Choi","volume":"382","first-page":"427","unstructured":null,"article-title":"Family history of gastric cancer and Helicobacter pylori treatment.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-024-03153-w","key":"jrv250035r29","year":"2024","issue":"11","author":"Pan","volume":"30","first-page":"3250","unstructured":null,"article-title":"Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2024.14887","key":"jrv250035r30","year":"2024","issue":"19","author":"Lee","volume":"332","first-page":"1642","unstructured":null,"article-title":"Screening for Helicobacter pylori to prevent gastric cancer: a pragmatic randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2020-320839","key":"jrv250035r31","year":"2020","issue":"12","author":"Ford","volume":"69","first-page":"2113","unstructured":null,"article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.","journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1111/den.14063","key":"jrv250035r32","year":"2022","issue":"3","author":"Mabe","volume":"34","first-page":"412","unstructured":null,"article-title":"Endoscopic screening for gastric cancer in Japan: current status and future perspectives.","journal-title":"Dig Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2017.01.029","key":"jrv250035r33","year":"2017","issue":"6","author":"Jun","volume":"152","first-page":"1319","unstructured":null,"article-title":"Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.4143/crt.2025.264","key":"jrv250035r34","year":"2025","issue":"2","author":"Park","volume":"57","first-page":"312","unstructured":null,"article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022.","journal-title":"Cancer Res Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/cas.15545","key":"jrv250035r35","year":"2022","issue":"11","author":"Narii","volume":"113","first-page":"3922","unstructured":null,"article-title":"Effectiveness of endoscopic screening for gastric cancer: the Japan public health center-based prospective study.","journal-title":"Cancer Sci","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2024.11.001","key":"jrv250035r36","year":"2025","issue":"2","author":"Shah","volume":"168","first-page":"405","unstructured":null,"article-title":"AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1111/apm.1965.64.1.31","key":"jrv250035r37","year":"1965","issue":null,"author":"Lauren","volume":"64","first-page":"31","unstructured":null,"article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification.","journal-title":"Acta Pathol Microbiol Scand","doi-asserted-by":"publisher"},{"DOI":"10.1038/nm.3850","key":"jrv250035r38","year":"2015","issue":"5","author":"Cristescu","volume":"21","first-page":"449","unstructured":null,"article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature13480","key":"jrv250035r39","year":"2014","issue":"7517","author":"Cancer Genome Atlas Research Network","volume":"513","first-page":"202","unstructured":null,"article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2018.03.010","key":"jrv250035r40","year":"2018","issue":"4","author":"Liu","volume":"33","first-page":"721","unstructured":null,"article-title":"Comparative molecular analysis of gastrointestinal adenocarcinomas.","journal-title":"Cancer Cell","doi-asserted-by":"publisher"},{"DOI":"10.1158/0008-5472.CAN-11-3893","key":"jrv250035r41","year":"2012","issue":"17","author":"Dulak","volume":"72","first-page":"4383","unstructured":null,"article-title":"Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.","journal-title":"Cancer Res","doi-asserted-by":"publisher"},{"DOI":"10.1136/jitc-2021-004080","key":"jrv250035r42","year":"2022","issue":"3","author":"Bai","volume":"10","first-page":null,"unstructured":null,"article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.","journal-title":"J Immunother Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjsurg.2017.10.030","key":"jrv250035r43","year":"2018","issue":"2","author":"Solsky","volume":"216","first-page":"286","unstructured":null,"article-title":"Gastric cancer diagnosis after presentation to the ED: the independent association of presenting location and outcomes.","journal-title":"Am J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/00000658-199321850-00002","key":"jrv250035r44","year":"1993","issue":"5","author":"Wanebo","volume":"218","first-page":"583","unstructured":null,"article-title":"Cancer of the stomach: a patient care study by the American College of Surgeons.","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/MEG.0000000000001251","key":"jrv250035r45","year":"2018","issue":"12","author":"Tang","volume":"30","first-page":"1497","unstructured":null,"article-title":"Iron deficiency anemia in gastric cancer: a Canadian retrospective review.","journal-title":"Eur J Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2015.04.003","key":"jrv250035r46","year":"2015","issue":"2","author":"Shaukat","volume":"82","first-page":"227","unstructured":null,"article-title":"The role of endoscopy in dyspepsia.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2005.09.019","key":"jrv250035r47","year":"2005","issue":"5","author":"Talley","volume":"129","first-page":"1753","unstructured":null,"article-title":"American Gastroenterological Association medical position statement: evaluation of dyspepsia.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2005.09.020","key":"jrv250035r48","year":"2005","issue":"5","author":"Talley","volume":"129","first-page":"1756","unstructured":null,"article-title":"American gastroenterological association technical review on the evaluation of dyspepsia.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amsu.2022.103411","key":"jrv250035r49","year":"2022","issue":null,"author":"Mranda","volume":"75","first-page":null,"unstructured":null,"article-title":"Revisiting the 8th AJCC system for gastric cancer: a review on validations, nomograms, lymph nodes impact, and proposed modifications.","journal-title":"Ann Med Surg (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1080/17474124.2018.1413348","key":"jrv250035r50","year":"2018","issue":"5","author":"Abdel-Rahman","volume":"12","first-page":"525","unstructured":null,"article-title":"Validation of the 8th AJCC staging system for gastric cancer in a population-based setting.","journal-title":"Expert Rev Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)32557-1","key":"jrv250035r51","year":"2019","issue":"10184","author":"Al-Batran","volume":"393","first-page":"1948","unstructured":null,"article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjsurg.2022.01.024","key":"jrv250035r52","year":"2022","issue":null,"author":"Sirody","volume":"224","first-page":"445","unstructured":null,"article-title":"Patterns of gastric cancer metastasis in the United States.","journal-title":"Am J Surg","doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.10740","key":"jrv250035r53","year":"2016","issue":"32","author":"Riihimäki","volume":"7","first-page":"52307","unstructured":null,"article-title":"Metastatic spread in patients with gastric cancer.","journal-title":"Oncotarget","doi-asserted-by":"publisher"},{"DOI":"10.6004/jnccn.2022.0008","key":"jrv250035r54","year":"2022","issue":"2","author":"Ajani","volume":"20","first-page":"167","unstructured":null,"article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology.","journal-title":"J Natl Compr Canc Netw","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2022.07.004","key":"jrv250035r55","year":"2022","issue":"10","author":"Lordick","volume":"33","first-page":"1005","unstructured":null,"article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.3390/diagnostics11010134","key":"jrv250035r56","year":"2021","issue":"1","author":"Ungureanu","volume":"11","first-page":"134","unstructured":null,"article-title":"Endoscopic ultrasound vs computed tomography for gastric cancer staging: a network meta-analysis.","journal-title":"Diagnostics (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-011-0017-5","key":"jrv250035r57","year":"2011","issue":"1","author":"Shimada","volume":"14","first-page":"13","unstructured":null,"article-title":"Japanese Gastric Cancer Association task force for research promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. a systematic review of the literature.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.27550","key":"jrv250035r58","year":"2012","issue":"22","author":"Smyth","volume":"118","first-page":"5481","unstructured":null,"article-title":"A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.","journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.21074","key":"jrv250035r59","year":"2005","issue":"11","author":"Chen","volume":"103","first-page":"2383","unstructured":null,"article-title":"Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.","journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2021.5340","key":"jrv250035r60","year":"2021","issue":"12","author":"Gertsen","volume":"156","first-page":null,"unstructured":null,"article-title":"18F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective Dutch cohort study (PLASTIC).","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLE.0000000000000451","key":"jrv250035r61","year":"2017","issue":"5","author":"Leeman","volume":"27","first-page":"369","unstructured":null,"article-title":"Multidetector computed tomography versus staging laparoscopy for the detection of peritoneal metastases in esophagogastric junctional and gastric cancer.","journal-title":"Surg Laparosc Endosc Percutan Tech","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2023.03.015","key":"jrv250035r62","year":"2023","issue":"3","author":"Forbes","volume":"98","first-page":"271","unstructured":null,"article-title":"American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-019-07417-5","key":"jrv250035r63","year":"2019","issue":"9","author":"Mogal","volume":"26","first-page":"2912","unstructured":null,"article-title":"In patients with localized and resectable gastric cancer, what is the optimal extent of lymph node dissection-D1 versus D2 versus D3?","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(11)61873-4","key":"jrv250035r64","year":"2012","issue":"9813","author":"Bang","volume":"379","first-page":"315","unstructured":null,"article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2503701","key":"jrv250035r65","year":"2025","issue":"3","author":"Janjigian","volume":"393","first-page":"217","unstructured":null,"article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2405195","key":"jrv250035r66","year":"2024","issue":"19","author":"Leong","volume":"391","first-page":"1810","unstructured":null,"article-title":"Preoperative chemoradiotherapy for resectable gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1112088","key":"jrv250035r67","year":"2012","issue":"22","author":"van Hagen","volume":"366","first-page":"2074","unstructured":null,"article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-021-11050-6","key":"jrv250035r68","year":"2022","issue":"4","author":"Nie","volume":"29","first-page":"2324","unstructured":null,"article-title":"Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.4143/crt.2020.313","key":"jrv250035r69","year":"2020","issue":"4","author":"Kim","volume":"52","first-page":"1178","unstructured":null,"article-title":"Adjuvant chemotherapy in microsatellite instability-high gastric cancer.","journal-title":"Cancer Res Treat","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.01124","key":"jrv250035r70","year":"2019","issue":"35","author":"Pietrantonio","volume":"37","first-page":"3392","unstructured":null,"article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clinre.2021.101691","key":"jrv250035r71","year":"2021","issue":"4","author":"Tran-Minh","volume":"45","first-page":null,"unstructured":null,"article-title":"Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01.","journal-title":"Clin Res Hepatol Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2021.0275","key":"jrv250035r72","year":"2021","issue":"6","author":"Chao","volume":"7","first-page":"895","unstructured":null,"article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00686","key":"jrv250035r73","year":"2023","issue":"2","author":"André","volume":"41","first-page":"255","unstructured":null,"article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2016.6762","key":"jrv250035r74","year":"2017","issue":"9","author":"Smyth","volume":"3","first-page":"1197","unstructured":null,"article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdn717","key":"jrv250035r75","year":"2009","issue":"4","author":"Kang","volume":"20","first-page":"666","unstructured":null,"article-title":"Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(10)61121-X","key":"jrv250035r76","year":"2010","issue":"9742","author":"Bang","volume":"376","first-page":"687","unstructured":null,"article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)02033-0","key":"jrv250035r77","year":"2023","issue":"10418","author":"Janjigian","volume":"402","first-page":"2197","unstructured":null,"article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2408121","key":"jrv250035r78","year":"2024","issue":"14","author":"Janjigian","volume":"391","first-page":"1360","unstructured":null,"article-title":"Pembrolizumab in HER2–positive gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00797-2","key":"jrv250035r79","year":"2021","issue":"10294","author":"Janjigian","volume":"398","first-page":"27","unstructured":null,"article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.01601","key":"jrv250035r80","year":"2024","issue":"17","author":"Janjigian","volume":"42","first-page":"2012","unstructured":null,"article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 Trial.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00515-6","key":"jrv250035r81","year":"2023","issue":"11","author":"Rha","volume":"24","first-page":"1181","unstructured":null,"article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00620-7","key":"jrv250035r82","year":"2023","issue":"10389","author":"Shitara","volume":"401","first-page":"1655","unstructured":null,"article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2409512","key":"jrv250035r83","year":"2024","issue":"12","author":"Shitara","volume":"391","first-page":"1159","unstructured":null,"article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-023-02465-7","key":"jrv250035r84","year":"2023","issue":"8","author":"Shah","volume":"29","first-page":"2133","unstructured":null,"article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(14)70420-6","key":"jrv250035r85","year":"2014","issue":"11","author":"Wilke","volume":"15","first-page":"1224","unstructured":null,"article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2004413","key":"jrv250035r86","year":"2020","issue":"25","author":"Shitara","volume":"382","first-page":"2419","unstructured":null,"article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(18)30739-3","key":"jrv250035r87","year":"2018","issue":"11","author":"Shitara","volume":"19","first-page":"1437","unstructured":null,"article-title":"Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-014-0402-y","key":"jrv250035r88","year":"2015","issue":"3","author":"Van Cutsem","volume":"18","first-page":"476","unstructured":null,"article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.3748/wjg.v22.i19.4619","key":"jrv250035r89","year":"2016","issue":"19","author":"Abrahao-Machado","volume":"22","first-page":"4619","unstructured":null,"article-title":"HER2 testing in gastric cancer: an update.","journal-title":"World J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2023-078876","key":"jrv250035r90","year":"2024","issue":null,"author":"Qiu","volume":"385","first-page":null,"unstructured":null,"article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdv625","key":"jrv250035r91","year":"2016","issue":"4","author":"Al-Batran","volume":"27","first-page":"673","unstructured":null,"article-title":"Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2022.01.015","key":"jrv250035r92","year":"2022","issue":null,"author":"Lorenzen","volume":"165","first-page":"48","unstructured":null,"article-title":"FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel—results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.","journal-title":"Eur J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1634/theoncologist.2018-0602","key":"jrv250035r93","year":"2019","issue":"4","author":"Klempner","volume":"24","first-page":"475","unstructured":null,"article-title":"Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis.","journal-title":"Oncologist","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(13)70549-7","key":"jrv250035r94","year":"2014","issue":"1","author":"Ford","volume":"15","first-page":"78","unstructured":null,"article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(13)61719-5","key":"jrv250035r95","year":"2014","issue":"9911","author":"Fuchs","volume":"383","first-page":"31","unstructured":null,"article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00280-012-2027-3","key":"jrv250035r96","year":"2013","issue":"2","author":"Sym","volume":"71","first-page":"481","unstructured":null,"article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.","journal-title":"Cancer Chemother Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.21037/jgo-23-1000","key":"jrv250035r97","year":"2024","issue":"1","author":"Jiang","volume":"15","first-page":"96","unstructured":null,"article-title":"Lack of clinical benefit from preoperative short-term parenteral nutrition on the clinical prognosis of patients treated with radical gastrectomy for gastric cancer: a two-center retrospective study based on propensity score matching analysis.","journal-title":"J Gastrointest Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1136/spcare-2024-005183","key":"jrv250035r98","year":"2025","issue":null,"author":"He","volume":null,"first-page":null,"unstructured":null,"article-title":"Early oral feeding post gastrectomy in gastric cancer: quasi-experimental study.","journal-title":"BMJ Support Palliat Care","doi-asserted-by":"publisher"},{"DOI":"10.1002/jso.23983","key":"jrv250035r99","year":"2015","issue":"2","author":"Dann","volume":"112","first-page":"195","unstructured":null,"article-title":"An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: a seven-institution analysis of 837 patients from the US gastric cancer collaborative.","journal-title":"J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(80)91406-3","key":"jrv250035r100","year":"1980","issue":"8175","author":"Tovey","volume":"1","first-page":"956","unstructured":null,"article-title":"Anaemia after partial gastrectomy: a neglected curable condition.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s002689900379","key":"jrv250035r101","year":"1998","issue":"3","author":"Bae","volume":"22","first-page":"254","unstructured":null,"article-title":"Nutritional status of gastric cancer patients after total gastrectomy.","journal-title":"World J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-017-0777-7","key":"jrv250035r102","year":"2018","issue":"4","author":"Yoo","volume":"21","first-page":"720","unstructured":null,"article-title":"Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14132712","key":"jrv250035r103","year":"2022","issue":"13","author":"Muszynski","volume":"14","first-page":"2712","unstructured":null,"article-title":"Vitamin D—the nutritional status of post-gastrectomy gastric cancer patients—systematic review.","journal-title":"Nutrients","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12029-023-01001-7","key":"jrv250035r104","year":"2024","issue":"2","author":"Cobani","volume":"55","first-page":"519","unstructured":null,"article-title":"Gastric cancer survivorship: multidisciplinary management, best practices and opportunities.","journal-title":"J Gastrointest Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1007/s101200200014","key":"jrv250035r105","year":"2002","issue":"2","author":"Kubo","volume":"5","first-page":"83","unstructured":null,"article-title":"Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.01254","key":"jrv250035r106","year":"2021","issue":"7","author":"Lu","volume":"39","first-page":"748","unstructured":null,"article-title":"Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled trial.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA"],"reference-count":106,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":106,"short-container-title":["JAMA"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jama.2025.20034","is_oa":false,"title":"Gastric Cancer","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":null}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1001/jama.2025.20034","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"trastuzumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"zolbetuximab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"CLDN18.2 Antibody","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"Cytotoxic Chemotherapy","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"HER2-Targeted Therapy","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"Specific trial methods and eligibility (e.g., PD-L1 thresholds, CLDN18.2 assay criteria) are not detailed.","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"The perioperative regimen including durvalumab is cited without study identifiers or dosing details.","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"This is a narrative review summarizing multiple studies, not a single trial.","value_numeric":null}],"summaries":{"what_studied":"Narrative review of gastric cancer epidemiology, presentation, screening, diagnosis, and treatment, with quantified outcomes for surgery, chemoimmunotherapy, and targeted therapy. It reports incidence (968,350 new cases and 659,853 deaths worldwide in 2022; 30,300 cases and 10,780 deaths in the US in 2025) and biomarker-driven management.","key_result":"At diagnosis, about 13% have localized, 15%–25% locally advanced, and 35%–65% metastatic disease; resection of localized cancer yields a 5-year relative survival of 75%, while fewer than 10% with metastatic disease live 5 years. In PD-L1–expressing tumors, adding nivolumab or pembrolizumab to chemotherapy adds ~3 months of survival; adding trastuzumab (ERBB2) or zolbetuximab (CLDN18.2) adds 3–4 months; early supportive care adds ~3 months; routine endoscopic screening from age 40 in high-incidence countries is associated with improved survival.","practice_takeaway":"Test for PD-L1, ERBB2, and CLDN18.2 in unresectable or metastatic gastric cancer to select immunotherapy or targeted therapy that can extend survival by several months. Use gastrectomy for localized disease and perioperative 5-fluorouracil/oxaliplatin/docetaxel plus durvalumab for more advanced resectable disease; initiate early supportive care, and in high-incidence regions, employ routine endoscopic screening from age 40."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"CLDN18.2 Antibody"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"CLDN18.2 Antibody"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"CLDN18.2 Antibody"}}}]]

Papers